A newly published paper by an international group of investigators has given us some further insight in to the roles of immunotherapeutic agents in the treatment of at least a subset of men with advanced forms of prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: defect, immunotherapy, mismatch, nivolumab, PD-1, pembrolizumab, repair | Leave a Comment »
So one of the more interesting things to be announced since your sitemaster arrived at the annual meeting of the American Urological Association (AUA) in San Francisco yesterday was this one:
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, Dendreon, Provenge, sipuleucel-T, surveillance, trial | 1 Comment »
The Society for Immunotherapy of Cancer has just issued a detailed statement on the role of immunotherapy in the management of prostate cancer. The full text of this article by McNeel et al. is available on line.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: guidelines, immunotherapy, Prostvac, Provenge, sipuleucel-T | 3 Comments »
There appears to be a high degree of confidence that Barvarian Nordic’s Prostvac will show positive results in the ongoing Phase III clinical trial in men with metastatic, castration-resistant prostate cancer. An early stage trial has now been initiated among men with much less advanced disease disease.
Filed under: Diagnosis, Drugs in development, Management, Risk, Treatment | Tagged: active surveillance, immunotherapy, Prostvac, trial | 5 Comments »
A number of readers will probably be interested in reading at least part of an interview with Dr. Susan Slovin of the Memorial Sloan Kettering Cancer Center that has just been published on the CancerNetwork web site.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: immunotherapy | Leave a Comment »
Alas, our friends at The Daily Telegraph in the UK seem to have managed to hyperinflate some early scientific findings into an overnight cure for prostate cancer in general and metastatic, castration-resistant prostate cancer in particular.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: B cell, checkpoint, inhibition, oxaliplatin, suppression | 8 Comments »
Starting today, we have a new contributor to the content of The “New” Prostate Cancer InfoLink.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: immunotherapy, radiation, radio-immunotherapy | 9 Comments »
Back in September 2011, a company called Advantagene initiated a randomized, placebo-controlled, Phase III clinical trial (the PrKT01 trial) of an immunotherapeutic agent known as AdV-tk, together with with standard external beam radiation therapy, in highly-defined patients with newly diagnosed, localized prostate cancer.
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: AdV-tk, immunotherapy, localized, radiation, trial | 1 Comment »
An article with the above title by Dr. Michael Glodé (a well-known medical oncologist at the University of Colorado in Denver) appears in the most recent issue of ASCO Connection.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: immunotherapy, sipuleucel-T | 14 Comments »
Many readers may want to scan through this article by Gina Kolata in today’s issue of The New York Times that deals with the developing potential of immunotherapeutic agents in the management of cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Leave a Comment »
A paper just published in Clinical Cancer Research has suggested that — at least for one immunotherapeutic agent (“vaccine”) in development for the treatment of advanced prostate cancer — it may be possible to define a subgroup of men who are more likely to respond well to treatment than others.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antibody, glycan, microarray, PROSTVAC-VF, serum | 4 Comments »
Prostate stem cell antigen (PSCA) is a cell surface antigen found in normal human prostate tissue and over-expressed in men who have prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer | Tagged: immunotherapy, pmPSCA, vaccine | Leave a Comment »
THE "NEW" PROSTATE CANCER INFOLINK 